Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:5738694.
doi: 10.1155/2016/5738694. Epub 2016 Jun 30.

Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites

Xiao-Jia Chen  1 , Xiao-Jing Zhang  1 , Yan-Mei Shui  2 , Jian-Bo Wan  1 , Jian-Li Gao  2
Affiliations
Review

Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites

Xiao-Jia Chen et al. Evid Based Complement Alternat Med. 2016.

Abstract

Recently, most anticancer drugs are derived from natural resources such as marine, microbial, and botanical sources, but the low success rates of chemotherapies and the development of multidrug resistance emphasize the importance of discovering new compounds that are both safe and effective against cancer. Ginseng types, including Asian ginseng, American ginseng, and notoginseng, have been used traditionally to treat various diseases, due to their immunomodulatory, neuroprotective, antioxidative, and antitumor activities. Accumulating reports have shown that ginsenosides, the major active component of ginseng, were helpful for tumor treatment. 20(S)-Protopanaxadiol (PDS) and 20(S)-protopanaxatriol saponins (PTS) are two characteristic types of triterpenoid saponins in ginsenosides. PTS holds capacity to interfere with crucial metabolism, while PDS could affect cell cycle distribution and prodeath signaling. This review aims at providing an overview of PTS and PDS, as well as their metabolites, regarding their different anticancer effects with the proposal that these compounds might be potent additions to the current chemotherapeutic strategy against cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Major metabolic processes of (a) 20(S)-protopanaxadiol- and (b) 20(S)-protopanaxatriol-type saponins. CK: compound K, PPD: 20(S)-protopanaxadiol, and PPT: 20(S)-protopanaxatriol.
Figure 2
Figure 2
Therapeutic targets of ginsenosides on cancer. PTS: 20(S)-protopanaxadiol saponins, PDS: 20(S)-protopanaxatriol saponins, PPT: protopanaxatriol, PPD: protopanaxadiol, and CK: compound K.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2015. CA Cancer Journal for Clinicians. 2015;65(1):5–29. doi: 10.3322/caac.21254. - DOI - PubMed
    1. Chen W., Zheng R., Zeng H., Zhang S., He J. Annual report on status of cancer in China, 2011. Chinese Journal of Cancer Research. 2015;27(1):2–12. doi: 10.3978/j.issn.1000-9604.2015.01.06. - DOI - PMC - PubMed
    1. Shen L. S. Bencao Gangmu. 1st. Beijing, China: Huaxia; 2005.
    1. The State Pharmacopoeia Commission of People’s Republic of China. Pharmacopoeia of the People's Republic of China. Beijing, China: Chemical Industry Press; 2000.
    1. State Administration of Traditional Chinese Medicine. ZhongHua Ben Cao JinXuan Ben. Shanghai, China: Shanghai Science and Technology; 1996.